levocetirizine / Generic mfg. - LARVOL DELTA

Generalized Maculopapular Eruption Induced by Minocycline: A Case Report. (PubMed, Cureus) - "The patient received supportive treatment with levocetirizine, and the rash disappeared completely within 48 hours. Causality assessment using the Naranjo Adverse Drug Reaction Probability Scale yielded a score of 6, and the World Health Organization-Uppsala Monitoring Centre (WHO-UMC) scale categorized the event as "probable." This case underlines the need for close monitoring of patients for cutaneous adverse drug reactions during minocycline therapy. Early identification and immediate withdrawal of the drug are essential for rapid recovery."

Journal • Cardiovascular • CNS Disorders • Critical care • Dermatology • Eosinophilia • Hypertension • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Pneumonia • Pruritus • Respiratory Diseases

Levocetirizine-induced paradoxical fixed drug eruption: A case report with causality assessment. (PubMed, Indian J Pharmacol) - "FDE due to levocetirizine, as well as with cetirizine, is less common in the literature. This case shows that antihistamines such as levocetirizine can trigger FDE in susceptible individuals. Improving clinical awareness through robust Pharmacovigilance activities, educating patients about triggers, and discouraging self-medication are crucial for preventing recurrence."

Journal • Immunology • CD8

Second-generation H1 antihistamines for the treatment of chronic urticaria: a network meta-analysis. (PubMed, Front Med (Lausanne)) - "To evaluate the efficacy and safety of 10 commonly used second-generation H1 antihistamines (cetirizine, levocetirizine, loratadine, desloratadine, ebastine, bilastine, olopatadine, rupatadine, fexofenadine, and mizolastine) at licensed doses in treating chronic urticaria using network meta-analysis. In addition, fexofenadine had the lowest incidence of adverse reactions. However, the conclusions of this study still need to be validated by further high-quality randomized controlled trials."

Journal • Retrospective data • Review • Chronic Spontaneous Urticaria • Dermatology • Immunology • Urticaria

Antihistamines for atopic dermatitis (eczema): systematic review and network meta-analysis of randomised trials. (PubMed, BMJ) - "Among patients with atopic dermatitis, adding H1 antihistamines probably results in a clinically unimportant reduction in atopic dermatitis severity and itch severity, and may not reduce sleep disturbance or atopic dermatitis exacerbations. First generation agents increase cognitive impairment and may increase treatment discontinuation because of adverse events. Cognitive impairment risk differs among second generation agents. These findings provide evidence against routine antihistamine use in atopic dermatitis management and will inform updated clinical guidelines."

Clinical • Journal • Retrospective data • Review • Alzheimer's Disease • Atopic Dermatitis • CNS Disorders • Cognitive Disorders • Dermatitis • Dermatology • Immunology • Sleep Disorder

Efficacy of Levocetirizine in Reducing Double-J Stent-Related Symptoms: A Double-Blind Pilot Randomized Controlled Trial. (PubMed, Adv Urol) - "These findings suggest that levocetirizine may be a well-tolerated adjunct therapy for managing stent discomfort. Trial registration: Clinical trial.gov.identifier: LBCTR2025075754."

Journal • Inflammation • Pain • Renal Calculi • Urolithiasis

Comparison of Non-sedating and Sedating Histamine H1-receptor Antagonist Premedication for Preventing Subcutaneous Daratumumab-associated Infusion-related Reactions: A Multicenter Retrospective Observational Study. (PubMed, Keio J Med) - "All patients in the nsAH group were treated with levocetirizine, while patients in the sAH group were treated with dexchlorpheniramine or diphenhydramine. This study showed that levocetirizine is not obviously inferior in efficacy and safety relative to sAH in preventing IRRs and drowsiness. Therefore, levocetirizine can be considered as a substitute for patients for whom the use of sAH is not acceptable."

Journal • Observational data • Retrospective data • Anesthesia • Hematological Malignancies • Multiple Myeloma • Oncology

Forecasting seasonal allergic rhinitis through integrated analysis of social media and online drug sales data. (PubMed, World Allergy Organ J) - "We analyzed daily data for urban Beijing from March 1, 2022 to October 15, 2024, including pollen concentration (grains per 1000 mm3), the Baidu search index for "allergic rhinitis," and online purchase rates of 4 oral second-generation H1-antihistamines (loratadine, desloratadine, cetirizine, levocetirizine) from the Meituan platform, standardized per 100,000 population. The ARIMAX (1,1,1) model integrating both pollen and Baidu Index achieved the best forecasting performance (1-day RMSE = 3.80, MAPE = 7.68%, PCC = 0.89) and consistently outperformed single-predictor models and the random-walk benchmark across all horizons. Pollen exposure influences antihistamine demand both directly and indirectly through public information-seeking behavior captured by the Baidu Index, and integrating environmental and digital data enables timely surveillance of seasonal allergic-rhinitis-related medication use."

Journal • Allergic Rhinitis • Immunology • Inflammation

Correlation of disease activity (Urticaria Activity Score over 7 Days) and quality of life (Chronic Urticaria Quality of Life Questionnaire) in patients with chronic spontaneous urticaria: A prospective observational study. (PubMed, Allergy Asthma Proc) - "All received second-generation H1-antihistamines (cetirizine, levocetirizine, or fexofenadine) with dose up-titration up to fourfold as needed per international urticaria guideline recommendations guideline recommendations. No patients required omalizumab during the study period...Routine use of both measures is recommended because UAS7 alone may underestimate the patient burden during remission. The total IgE value and AEC are not reliable surrogate markers of CSU severity or QoL in this exploratory cohort."

HEOR • Journal • Observational data • Chronic Spontaneous Urticaria • Dermatology • Immunology • Pruritus • Urticaria

NEWER-GENERATION H1 PLUS H2 ANTIHISTAMINES AS PREMEDICATION TO REDUCE RITUXIMAB-INDUCED HYPERSENSITIVITY REACTIONS: A RETROSPECTIVE STUDY (MASCC-ISOO 2026) - "Methods A retrospective cohort study was performed to compare two premedication protocols — a conventional regimen (Protocol A: diphenhydramine, dexamethasone, paracetamol) and a modified regimen (Protocol B: levocetirizine, famotidine, dexamethasone, paracetamol)—for preventing rituximab-induced hypersensitivity reactions (HSRs) in patients with hematologic malignancies receiving their first rituximab infusion at Ramathibodi hospital between April 2023 and June 2025. Conclusions The modified premedication protocol, which included newer-generation H1-antihistamines and H2-antihistamines, was associated with a significantly lower incidence of rituximab-induced HSRs compared with the conventional regimen. These findings support optimization of premedication strategies to improve the safety of rituximab treatment."

Retrospective data • Cardiovascular • Hematological Malignancies • Immunology

Second-generation H1 antihistamine use with survival and immune-related outcomes in lung cancer and melanoma patients receiving immune checkpoint inhibitors. (ASCO 2026) - "Adult patients (≥18 years) with melanoma or lung cancer receiving ICIs (pembrolizumab, nivolumab, ipilimumab, atezolizumab, durvalumab, cemiplimab, or avelumab) were identified. Patients were categorized by exposure to second-generation H1 antihistamines (cetirizine, loratadine, fexofenadine, desloratadine, or levocetirizine) within 3 months before or during ICI initiation... Second-generation H1 antihistamine use was associated with improved early survival and reduced healthcare utilization among melanoma and lung cancer patients treated with ICIs, without a significant increase in irAEs. Despite the retrospective design and potential confounding, prospective validation is warranted."

Checkpoint inhibition • Clinical • Lung Cancer • Melanoma • Musculoskeletal Diseases • Neutropenia • Oncology • Solid Tumor

Basophil Testing Beyond Positivity: Are There More Endotypes in Chronic Spontaneous Urticaria? (EAACI 2026) - "Case description: We report a 34-year-old woman with severe CSU characterized by daily wheals and recurrent facial angioedema, refractory to multiple second-generation H1-antihistamines (loratadine, levocetirizine, bilastine and rupatadine) at up to fourfold doses, as well as montelukast 10 mg...Given severe corticosteroid-dependent CSU refractory to high-dose antihistamines, omalizumab was initiated, leading to rapid clinical improvement, complete corticosteroid withdrawal and sustained disease control after one month. Despite severe, treatment-refractory disease, the absence of serum-induced basophil activation argues against classical type IIb autoimmune CSU. Detailed basophil phenotyping revealed increased basal activation, highlighting the limitations of a binary BAT interpretation and supporting the existence of additional, incompletely characterized CSU endotypes."

Late-breaking abstract • Immunology • Inflammation • CD69

Efficacy and Safety of Histaglobulin as an Adjunctive Therapy in Chronic Spontaneous Urticaria: A prospective, single-arm, self-controlled, interventional study (EAACI 2026) - "We enrolled 17 adults (aged 18–60 years) with CSU inadequately controlled by levocetirizine 5 mg daily (UAS7 ≥7 or UCT <15). This proof-of-concept study establishes that Histaglobulin could be a practical, cost-effective alternative intervention. Future studies need to evaluate Histaglobulin in patients refractory to 4-fold up-dosed antihistamines before starting Omalizumab/Cyclosporine if there is an affordability issue."

Clinical • Immunology

Multiple Hypersensitivity Reactions to Chemically Unrelated H1 Antihistamines: Two Case Reports (EAACI 2026) - "During subsequent diagnostic work-up, double-blindplacebo-controlled provocation tests (DBPC) were performed with levocetirizine (10mg), fexofenadine (180 mg), desloratadine (5 mg), and bilastine (20 mg)...Subsequently, a provocation test with rupatadine (cumulativedose 10 mg) was performed... The presented cases confirm the possibility of paradoxical hypersensitivity reactionsto antihistamines. To the best of our knowledge, this is the first report describinghypersensitivity reactions to multiple H1 antihistamines with different chemicalstructures."

Case report • Clinical • Immunology

The paradox of treatment: H1-antihistamines-induced urticaria in a patient with chronic spontaneous urticaria (EAACI 2026) - "She was also suffering from allergic rhinitis due to the pollen allergy and had a history of hypersensitivity cutaneous reaction to ibuprofen...Urticaria exacerbations were caused by multiple antihistamines, including piperidine (rupatadine) and piperazine (cetirizine and levocetirizine) derivatives... Although uncommon, antihistamine-induced urticaria in CSU patients may occur and must not be underestimated. Considering the proposed pathogenic hypotheses, patients with an atopic background and a history of cross-reactivity to nonsteroidal anti-inflammatory drugs may be at an increased risk."

Clinical • Allergic Rhinitis • Allergy • Immunology • Inflammation

Mimicry of delayed pressure urticaria. Clinical case reports (EAACI 2026) - "C4 0.28 g/l (0.15-0.57), C1q antibody negative.Several episodes of hospitalization with the need for dexamethasone, with plasmapheresis due to the low effectiveness of systemic steroids...With levocetirizine therapy at an escalating dose of 20 mg/day, the symptoms regressed completely within two days of starting therapy...Since 2023, symptoms increased in severity and frequency: swelling of the feet and face,weakness, fatigue, and arthralgia.120 mg of fexofenadine - ineffective...A low incidence of the disease has also been described among all types of urticaria—from 0.7 to 3.5%. These clinical cases demonstrate the difficulties of diagnosis due to the delayed onset of symptoms and their prolonged regression, which is uncharacteristic of urticaria, the variety of clinical manifestations, the possible presence of systemic symptoms, and elevated markers of a systemic inflammatory response."

Case report • Clinical • Immunology • Inflammation • Systemic Inflammatory Response Syndrome

Green synthesis of Illicium verum-derived novel semiconducting Ag/Fe/Cu-trimetallic nanocomposites: A dual-functional platform for selective detection of pharmaceutical compounds and light-independent degradation of organic dyes. (PubMed, RSC Adv) - "The limit of detection values for levofloxacin and levocetirizine were found to be 4.43 µM and 5.49 µM, respectively. The findings revealed that the rate of degradation was substantially enhanced (93.48% in 2 h) in the presence of nanocomposites as compared to bare H2O2 (33% in 2 h). Our study explores the potential use of semiconducting Ag/Fe/Cu-TNAs as bio-sensors and catalysts for promising and viable applications, especially in wastewater treatment, a step forward to meet the 17 Sustainable Development Goals (SDGs)."

Journal

A Prospective, Single-Arm, Self-Controlled, Interventional Study on Efficacy and Safety of Histaglobulin as Add-On Therapy in Chronic Spontaneous Urticaria (EADV-Sp 2026) - "We enrolled 17 adults (aged 18–60 years) with CSU inadequately controlled by levocetirizine 5 mg daily (UAS7 ≥7 or UCT <15). This proof-of-concept study establishes Histaglobulin could be a practical, cost- effective alternative intervention. Future studies need to evaluate Histaglobulin in patients refractory to 4-fold up-dosed antihistamines before starting Omalizumab/Cyclosporine if there is an affordability issue."

Clinical • Chronic Spontaneous Urticaria • Dermatology • Immunology • Urticaria

Adjunctive H₁-Antihistamines in Isotretinoin Therapy for Acne Management (EADV-Sp 2026) - "Recent trials suggest that adding an oral H1-antihistamine such as desloratadine or levocetirizine may improve treatment tolerability and clinical response. Benefits were most consistent in trials using desloratadine. Further high-quality randomized studies with standardized outcome reporting are needed to clarify long-term efficacy and to compare different antihistamines more directly."

Acne Vulgaris • Inflammation • Pruritus

TREATMENT PATTERNS, HEALTHCARE RESOURCE UTILIZATION, AND DIRECT MEDICAL COSTS OF CHRONIC URTICARIA IN CHINA: A REAL-WORLD STUDY (ISPOR 2026) - "Over 90% received second-generation antihistamines, mainly ebastine, levocetirizine, and cetirizine. Omalizumab was used by 573 (Tianjin) and 399 (Xiamen) patients, primarily at 300 mg... This real-world study provides comprehensive insights into CU treatment patterns, healthcare resource utilization, and economic burden in China, informing decision-making for CU management and healthcare resource allocation."

Clinical • HEOR • Real-world • Real-world evidence • CNS Disorders • Dermatology • Dermatopathology • Immunology • Infectious Disease • Respiratory Diseases • Sleep Disorder • Urticaria

Comparison of Allergic Rhinitis Treatments on Utilities and Quality of Life: A MASK-air Study. (PubMed, Clin Exp Allergy) - "Fixed combinations of intranasal antihistamines and corticosteroids were associated with better quality-of-life than oral antihistamines and intranasal antihistamines. These findings could support future cost-effectiveness analyses."

HEOR • Journal • Allergic Rhinitis • Asthma • Conjunctivitis • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology • Pulmonary Disease • Respiratory Diseases

AI-assisted pill identification to improve medication reconciliation in ENT clinics (COSM 2026) - " A curated dataset of pill images representing five commonly used antihistaminesAllegra (fexofenadine), Benadryl (diphenhydramine), Claritin (loratadine), Xyzal (levocetirizine), and Zyrtec (cetirizine)was assembled from public sources and divided into training (75%) and validation (25%) subsets. CNN-based pill identification demonstrates strong potential to augment medication reconciliation in clinics by accurately distinguishing commonly used antihistamines. Misclassification confined to a single class underscores the need for expanded datasets and real-world validation. Integration of AI-assisted pill recognition into clinical workflows and electronic medical records could substantially reduce reconciliation errors, enhance patient safety, and streamline care."

Elucidating the Multi-Target Anti-Pruritic Mechanism of Polygonatum odoratum via Integrated Network Pharmacology, Molecular Simulations, and GEO Dataset Validation. (PubMed, Curr Issues Mol Biol) - "GEO dataset validation reinforced key results. This study suggests that Polygonatum odoratum may exert anti-pruritic effects through the combined actions of inflammation suppression, skin barrier repair, and neural modulation, revealing a novel multi-target mechanism for pruritus therapy and potential synergy with levocetirizine."

Journal • Dermatology • Inflammation • Pruritus • IL17A

Suspected Cutaneous Adverse Reaction Due to Oral Consumption of Siddha Polyherbo-Mineral Formulation, Gandhaga Rasayanam: A Case Report. (PubMed, Curr Drug Saf) - "This case highlights the potential for adverse reactions even with traditionally regarded safe Ayush formulations and emphasizes the need for vigilant pharmacovigilance and systematic documentation of adverse events to ensure patient safety."

Journal • Dermatology • Pruritus

PREVAIL: A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) (clinicaltrials.gov) - P3 | N=454 | Recruiting | Sponsor: Biogen

Trial initiation date • Glomerulonephritis • IgA Nephropathy • Renal Disease

Anaphylaxis due to progesterone hypersensitivity: A rare cause of recurrent anaphylaxis. (PubMed, Asia Pac Allergy) - "Daily antihistamine therapy with levocetirizine was initiated to mitigate the risk of endogenous progesterone-induced reactions. This case highlights the importance of considering PH in the differential diagnosis of recurrent anaphylaxis in women, especially those with cyclical allergic symptoms or a history of exogenous progesterone exposure. Early recognition and appropriate management are crucial to prevent potentially life-threatening events."

Journal • Dermatology • Gynecology • Immunology • Urticaria